can you take glp 1 with crohn's disease Pharmacological interventions for obesity in patients inflammatory bowel disease: A systematic review of GLP-1 receptor agonist efficacy and safety GLP-1s and Crohn's Disease: Safety,

Some GLP-1 medicines are licensed for weight management in individuals with obesity or related health concerns

Potential risks may include but are not limited to: vasovagal response (passing out), new or increased pain, infection, bleeding, permanent skin changes, allergic or unexpected drug reaction with minor or major consequences, and unintended nerve injury

En suplementos deportivos suele verse entre 3 y 6 g/da , pero no es una dosis universal

The standard dose for women is 1.75 mg subcutaneously, delivered via an autoinjector pen, taken about 45 minutes before anticipated sexual activity

Individual variation: Individual responses to L-carnitine supplementation can vary based on diet, genetics, and health status